Aurobindo's latest bid comes on the heels of last month’s shot at Israeli drug maker Teva's UK product portfolio, where it was outbid by rival Intas Pharmaceuticals.
With the acquisition of Teva’s products, sold through erstwhile Actavis’ operations, Intas is set to emerge as a top player in the UK generics market.
"In order to strengthen the focus on core areas of business and to improve long-term competitiveness in a rapidly changing pharmaceutical market by aligning with the management framework and strategy, it was imperative to sell off the biotech unit as a going concern on slump sale basis," the drug firm added.
Swiss biotechnology giant Roche has sued Ahmedabad-based drug maker Intas Pharmaceuticals in Delhi High Court, alleging infringement of its patent rights over Mircera.
Intas is the only domestic firm with two biosimilars filed for registration in the US and it looks to deliver affordable and innovative pharmaceutical solutions in India.
Further strengthen its business in European and non-European countries, Ahmedabad based Intas Pharmaceuticals Ltd has acquired hospital business of Combino Pharm in Spain and Portugal for an undisclosed sum.
The product has recently been introduced under the brand Accofil and has already won two prestigious tenders, in Netherlands and the UK.
Get updates on your preferred social platform
Follow us for the latest news, insider access to events and more.
